HJ Research delivers in-depth insights on the global Oncolytic Virus Immunotherapy market in its upcoming report titled, Global Oncolytic Virus Immunotherapy Market Report 2018-2029. According to this study, the global Oncolytic Virus Immunotherapy market is estimated to be valued at XX Million US$ in 2023 and is projected to reach XX Million US$ by 2029, expanding at a CAGR of XX% during the forecast period. The report on Oncolytic Virus Immunotherapy market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc.
This report studies the Oncolytic Virus Immunotherapy market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global Oncolytic Virus Immunotherapy industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Oncolytic Virus Immunotherapy industry.
Global Oncolytic Virus Immunotherapy market: competitive landscape analysis
This report contains the major manufacturers analysis of the global Oncolytic Virus Immunotherapy industry. By understanding the operations of these manufacturers (revenue and gross margin from 2018 to 2023), the reader can understand the strategies and collaborations that the manufacturers are focusing on combat competition in the market.
Global Oncolytic Virus Immunotherapy market: types and end industries analysis
The research report includes specific segments such as end industries and product types of Oncolytic Virus Immunotherapy. The report provides market size for each type and end industry from 2018 to 2023. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global Oncolytic Virus Immunotherapy market: regional analysis
Geographically, this report is segmented into several key countries, with market size, growth rate of Oncolytic Virus Immunotherapy in these countries from 2018 to 2023, which covering United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, China, Japan, Korea, India, Australia, Indonesia, Vietnam, Turkey, Saudi Arabia, South Africa, Egypt, Brazil, Mexico, Argentina, Colombia.
Key players in global Oncolytic Virus Immunotherapy market include:
Merck
Amgen
TILT Biotherapeutics
Oncorus
Sorrento Therapeutics
Shanghai Sunway Biotech
Market segmentation, by product types:
Engineering Oncolytic Viruses
Wild-Type Oncolytic Viruses
Market segmentation, by applications:
Hospitals
Clinics
Ambulatory Surgical Centers
1 Industry Overview of Oncolytic Virus Immunotherapy
1.1 Research Scope
1.2 Market Segmentation by Types of Oncolytic Virus Immunotherapy
1.3 Market Segmentation by End Users of Oncolytic Virus Immunotherapy
1.4 Market Dynamics Analysis of Oncolytic Virus Immunotherapy
1.4.1 Market Drivers
1.4.2 Market Challenges
1.4.3 Market Opportunities
1.4.4 Porter’s Five Forces
2 Major Manufacturers Analysis of Oncolytic Virus Immunotherapy Industry
2.1 Merck
2.1.1 Company Overview
2.1.2 Main Products and Specifications
2.1.3 Oncolytic Virus Immunotherapy Revenue and Gross Margin (2018-2023)
2.1.4 Contact Information
2.2 Amgen
2.2.1 Company Overview
2.2.2 Main Products and Specifications
2.2.3 Oncolytic Virus Immunotherapy Revenue and Gross Margin (2018-2023)
2.2.4 Contact Information
2.3 TILT Biotherapeutics
2.3.1 Company Overview
2.3.2 Main Products and Specifications
2.3.3 Oncolytic Virus Immunotherapy Revenue and Gross Margin (2018-2023)
2.3.4 Contact Information
2.4 Oncorus
2.4.1 Company Overview
2.4.2 Main Products and Specifications
2.4.3 Oncolytic Virus Immunotherapy Revenue and Gross Margin (2018-2023)
2.4.4 Contact Information
2.5 Sorrento Therapeutics
2.5.1 Company Overview
2.5.2 Main Products and Specifications
2.5.3 Oncolytic Virus Immunotherapy Revenue and Gross Margin (2018-2023)
2.5.4 Contact Information
2.6 Shanghai Sunway Biotech
2.6.1 Company Overview
2.6.2 Main Products and Specifications
2.6.3 Oncolytic Virus Immunotherapy Revenue and Gross Margin (2018-2023)
2.6.4 Contact Information
3 Global Oncolytic Virus Immunotherapy Market Analysis by Regions, Manufacturers, Types and End Users
3.1 Global Sales Revenue of Oncolytic Virus Immunotherapy by Regions (2018-2023)
3.2 Global Sales Revenue of Oncolytic Virus Immunotherapy by Manufacturers (2018-2023)
3.3 Global Sales Revenue of Oncolytic Virus Immunotherapy by Types (2018-2023)
3.4 Global Sales Revenue of Oncolytic Virus Immunotherapy by End Users (2018-2023)
4 Northern America Oncolytic Virus Immunotherapy Market Analysis by Countries, Types and End Users
4.1 Northern America Oncolytic Virus Immunotherapy Sales Revenue Analysis by Countries (2018-2023)
4.2 Northern America Oncolytic Virus Immunotherapy Sales Revenue Analysis by Types (2018-2023)
4.3 Northern America Oncolytic Virus Immunotherapy Sales Revenue Analysis by End Users (2018-2023)
4.4 United States Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
4.5 Canada Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
5 Europe Oncolytic Virus Immunotherapy Market Analysis by Countries, Types and End Users
5.1 Europe Oncolytic Virus Immunotherapy Sales Revenue Analysis by Countries (2018-2023)
5.2 Europe Oncolytic Virus Immunotherapy Sales Revenue Analysis by Types (2018-2023)
5.3 Europe Oncolytic Virus Immunotherapy Sales Revenue Analysis by End Users (2018-2023)
5.4 Germany Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
5.5 France Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
5.6 UK Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
5.7 Italy Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
5.8 Russia Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
5.9 Spain Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
5.10 Netherlands Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
6 Asia Pacific Oncolytic Virus Immunotherapy Market Analysis by Countries, Types and End Users
6.1 Asia Pacific Oncolytic Virus Immunotherapy Sales Revenue Analysis by Countries (2018-2023)
6.2 Asia Pacific Oncolytic Virus Immunotherapy Sales Revenue Analysis by Types (2018-2023)
6.3 Asia Pacific Oncolytic Virus Immunotherapy Sales Revenue Analysis by End Users (2018-2023)
6.4 China Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
6.5 Japan Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
6.6 Korea Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
6.7 India Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
6.8 Australia Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
6.9 Indonesia Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
6.10 Vietnam Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
7 Latin America Oncolytic Virus Immunotherapy Market Analysis by Countries, Types and End Users
7.1 Latin America Oncolytic Virus Immunotherapy Sales Revenue Analysis by Countries (2018-2023)
7.2 Latin America Oncolytic Virus Immunotherapy Sales Revenue Analysis by Types (2018-2023)
7.3 Latin America Oncolytic Virus Immunotherapy Sales Revenue Analysis by End Users (2018-2023)
7.4 Brazil Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
7.5 Mexico Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
7.6 Argentina Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
7.7 Colombia Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
8 Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis by Countries, Types and End Users
8.1 Middle East & Africa Oncolytic Virus Immunotherapy Sales Revenue Analysis by Countries (2018-2023)
8.2 Middle East & Africa Oncolytic Virus Immunotherapy Sales Revenue Analysis by Types (2018-2023)
8.3 Middle East & Africa Oncolytic Virus Immunotherapy Sales Revenue Analysis by End Users (2018-2023)
8.4 Turkey Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
8.5 Saudi Arabia Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
8.6 South Africa Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
8.7 Egypt Oncolytic Virus Immunotherapy Sales Revenue Analysis (2018-2023)
9 Marketing Channel, Distributors and Traders Analysis
9.1 Marketing Channel
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Distributors and Traders
10 Global Oncolytic Virus Immunotherapy Market Forecast by Regions, Countries, Manufacturers, Types and End Users
10.1 Global Sales Revenue Forecast of Oncolytic Virus Immunotherapy by Regions (2024-2029)
10.2 Global Sales Revenue Forecast of Oncolytic Virus Immunotherapy by Types (2024-2029)
10.3 Global Sales Revenue Forecast of Oncolytic Virus Immunotherapy by End Users (2024-2029)
10.4 Global Revenue Forecast of Oncolytic Virus Immunotherapy by Countries (2024-2029)
10.4.1 United States Revenue Forecast (2024-2029)
10.4.2 Canada Revenue Forecast (2024-2029)
10.4.3 Germany Revenue Forecast (2024-2029)
10.4.4 France Revenue Forecast (2024-2029)
10.4.5 UK Revenue Forecast (2024-2029)
10.4.6 Italy Revenue Forecast (2024-2029)
10.4.7 Russia Revenue Forecast (2024-2029)
10.4.8 Spain Revenue Forecast (2024-2029)
10.4.9 Netherlands Revenue Forecast (2024-2029)
10.4.10 China Revenue Forecast (2024-2029)
10.4.11 Japan Revenue Forecast (2024-2029)
10.4.12 Korea Revenue Forecast (2024-2029)
10.4.13 India Revenue Forecast (2024-2029)
10.4.14 Australia Revenue Forecast (2024-2029)
10.4.15 Indonesia Revenue Forecast (2024-2029)
10.4.16 Vietnam Revenue Forecast (2024-2029)
10.4.17 Brazil Revenue Forecast (2024-2029)
10.4.18 Mexico Revenue Forecast (2024-2029)
10.4.19 Argentina Revenue Forecast (2024-2029)
10.4.20 Colombia Revenue Forecast (2024-2029)
10.4.21 Turkey Revenue Forecast (2024-2029)
10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
10.4.23 South Africa Revenue Forecast (2024-2029)
10.4.24 Egypt Revenue Forecast (2024-2029)
11 Industry Chain Analysis of Oncolytic Virus Immunotherapy
11.1 Upstream Analysis of Oncolytic Virus Immunotherapy
11.2 Downstream Major Consumers Analysis of Oncolytic Virus Immunotherapy
11.3 Major Suppliers of Oncolytic Virus Immunotherapy with Contact Information
11.4 Supply Chain Relationship Analysis of Oncolytic Virus Immunotherapy
12 Oncolytic Virus Immunotherapy New Project Investment Feasibility Analysis
12.1 Oncolytic Virus Immunotherapy New Project SWOT Analysis
12.2 Oncolytic Virus Immunotherapy New Project Investment Feasibility Analysis
12.2.1 Project Name
12.2.2 Investment Budget
12.2.3 Project Product Solutions
12.2.4 Project Schedule
13 Oncolytic Virus Immunotherapy Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.2 References and Data Sources
14.2.1 Primary Sources
14.2.2 Secondary Paid Sources
14.2.3 Secondary Public Sources
14.3 Abbreviations and Units of Measurement
14.4 Author Details
14.5 Disclaimer
Table Types of Oncolytic Virus Immunotherapy
Table End Users of Oncolytic Virus Immunotherapy
Figure Market Drivers Analysis of Oncolytic Virus Immunotherapy
Figure Market Challenges Analysis of Oncolytic Virus Immunotherapy
Figure Market Opportunities Analysis of Oncolytic Virus Immunotherapy
Table Market Drivers Analysis of Oncolytic Virus Immunotherapy
Table Merck Information List
Figure Oncolytic Virus Immunotherapy Specifications of Merck
Table Oncolytic Virus Immunotherapy Revenue (Million USD) and Gross Margin of Merck (2018-2023)
Figure Oncolytic Virus Immunotherapy Revenue (Million USD) and Global Market Share of Merck (2018-2023)
Table Amgen Information List
Figure Oncolytic Virus Immunotherapy Specifications of Amgen
Table Oncolytic Virus Immunotherapy Revenue (Million USD) and Gross Margin of Amgen (2018-2023)
Figure Oncolytic Virus Immunotherapy Revenue (Million USD) and Global Market Share of Amgen (2018-2023)
Table TILT Biotherapeutics Information List
Figure Oncolytic Virus Immunotherapy Specifications of TILT Biotherapeutics
Table Oncolytic Virus Immunotherapy Revenue (Million USD) and Gross Margin of TILT Biotherapeutics (2018-2023)
Figure Oncolytic Virus Immunotherapy Revenue (Million USD) and Global Market Share of TILT Biotherapeutics (2018-2023)
Table Oncorus Information List
Figure Oncolytic Virus Immunotherapy Specifications of Oncorus
Table Oncolytic Virus Immunotherapy Revenue (Million USD) and Gross Margin of Oncorus (2018-2023)
Figure Oncolytic Virus Immunotherapy Revenue (Million USD) and Global Market Share of Oncorus (2018-2023)
Table Sorrento Therapeutics Information List
Figure Oncolytic Virus Immunotherapy Specifications of Sorrento Therapeutics
Table Oncolytic Virus Immunotherapy Revenue (Million USD) and Gross Margin of Sorrento Therapeutics (2018-2023)
Figure Oncolytic Virus Immunotherapy Revenue (Million USD) and Global Market Share of Sorrento Therapeutics (2018-2023)
Table Shanghai Sunway Biotech Information List
Figure Oncolytic Virus Immunotherapy Specifications of Shanghai Sunway Biotech
Table Oncolytic Virus Immunotherapy Revenue (Million USD) and Gross Margin of Shanghai Sunway Biotech (2018-2023)
Figure Oncolytic Virus Immunotherapy Revenue (Million USD) and Global Market Share of Shanghai Sunway Biotech (2018-2023)
Table Global Revenue (Million USD) of Oncolytic Virus Immunotherapy by Regions (2018-2023)
Table Global Revenue (Million USD) of Oncolytic Virus Immunotherapy by Manufacturers (2018-2023)
Table Global Revenue (Million USD) of Oncolytic Virus Immunotherapy by Types (2018-2023)
Table Global Revenue (Million USD) of Oncolytic Virus Immunotherapy by End Users (2018-2023)
Table Northern America Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2018-2023)
Table Northern America Oncolytic Virus Immunotherapy Revenue (Million USD) by Types (2018-2023)
Table Northern America Oncolytic Virus Immunotherapy Revenue (Million USD) by End Users (2018-2023)
Figure United States Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Canada Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Table Europe Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2018-2023)
Table Europe Oncolytic Virus Immunotherapy Revenue (Million USD) by Types (2018-2023)
Table Europe Oncolytic Virus Immunotherapy Revenue (Million USD) by End Users (2018-2023)
Figure Germany Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure France Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure UK Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Italy Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Russia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Spain Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Netherlands Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Table Asia Pacific Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2018-2023)
Table Asia Pacific Oncolytic Virus Immunotherapy Revenue (Million USD) by Types (2018-2023)
Table Asia Pacific Oncolytic Virus Immunotherapy Revenue (Million USD) by End Users (2018-2023)
Figure China Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Japan Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Korea Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure India Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Australia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Indonesia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Vietnam Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Table Latin America Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2018-2023)
Table Latin America Oncolytic Virus Immunotherapy Revenue (Million USD) by Types (2018-2023)
Table Latin America Oncolytic Virus Immunotherapy Revenue (Million USD) by End Users (2018-2023)
Figure Brazil Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Mexico Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Argentina Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Colombia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Table Middle East & Africa Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2018-2023)
Table Middle East & Africa Oncolytic Virus Immunotherapy Revenue (Million USD) by Types (2018-2023)
Table Middle East & Africa Oncolytic Virus Immunotherapy Revenue (Million USD) by End Users (2018-2023)
Figure Turkey Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Saudi Arabia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure South Africa Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Figure Egypt Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2018-2023)
Table Global Revenue (Million USD) Forecast of Oncolytic Virus Immunotherapy by Regions (2024-2029)
Table Global Revenue (Million USD) Forecast of Oncolytic Virus Immunotherapy by Types (2024-2029)
Table Global Revenue (Million USD) Forecast of Oncolytic Virus Immunotherapy by End Users (2024-2029)
Table Major Consumers with Contact Information of Oncolytic Virus Immunotherapy
Table Major Suppliers of Oncolytic Virus Immunotherapy with Contact Information
Figure Supply Chain Relationship Analysis of Oncolytic Virus Immunotherapy
Table New Project SWOT Analysis of Oncolytic Virus Immunotherapy
Table Project Appraisal and Financing
Table New Project Construction Period
Table New Project Investment Feasibility Analysis of Oncolytic Virus Immunotherapy
Table Research Programs/Design for This Report
Table Key Data Information from Primary Sources
Table Key Data Information from Secondary Sources
Table Part of Interviewees Record List of Oncolytic Virus Immunotherapy Industry
Table Part of References List of Oncolytic Virus Immunotherapy Industry
Table Units of Measurement List
Table Part of Author Details List of Oncolytic Virus Immunotherapy Industry
HJ Research employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. At HJ Research, our researchers and domain experts use a unique blend of primary and secondary research, with validation and iterations at every stage, in order to minimize deviation and present the most accurate analysis of the Oncolytic Virus Immunotherapy industry. Critical elements of methodology employed for all our studies include:
Secondary Sources:
The research team first works with national bureau of statistics, national customs, market research association, state information center, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Secondary sources are mainly from press releases, company reports and publications, non-profit organizations, industry associations, government publications, economic and demographic data and customs data. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Primary Research:
In the primary research process, for comprehensive understanding of the Oncolytic Virus Immunotherapy market, it is essential to understand the complete value chain and in order to facilitate this, we collect data from Oncolytic Virus Immunotherapy manufacturers, Oncolytic Virus Immunotherapy raw material suppliers, Oncolytic Virus Immunotherapy distributors as well as buyers. The primary sources from the supply side include Oncolytic Virus Immunotherapy manufacturers, opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the Oncolytic Virus Immunotherapy raw materials suppliers and producers, etc. The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users, and related key executives from various key companies and organizations operating in the global market.
Technical issues and trends are obtained from surveys, technical symposia and trade journals. Technical data is also gathered from intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered.
Statistical Model and Data Analysis:
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise. Qualitative analysis includes: Oncolytic Virus Immunotherapy industry landscape and trends, Oncolytic Virus Immunotherapy market dynamics and key issues, Oncolytic Virus Immunotherapy technology landscape, market opportunities, porter’s analysis and PESTEL analysis, Oncolytic Virus Immunotherapy competitive landscape and component benchmarking, policy and regulatory scenario. Quantitative analysis includes: Oncolytic Virus Immunotherapy market size and forecast by regions, Oncolytic Virus Immunotherapy market size and forecast by application, Oncolytic Virus Immunotherapy market size and forecast by types, Oncolytic Virus Immunotherapy company market share etc.
Quality Control:
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the HJ Research’s internal quality process.
